These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37264960)

  • 41. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C; Wang Q; Yan X; Wang J
    Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution.
    Fietkau R; Putz F; Lahmer G; Semrau S; Buslei R
    Strahlenther Onkol; 2013 Dec; 189(12):993-5. PubMed ID: 24177536
    [No Abstract]   [Full Text] [Related]  

  • 44. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
    Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
    Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.
    Yang H; Wei D; Yang K; Tang W; Luo Y; Zhang J
    Neurochem Res; 2014 Dec; 39(12):2277-87. PubMed ID: 25230908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples.
    Filipits M; Preusser M; Hainfellner JA; Spiegl-Kreinecker S; Berghoff AS; Lai EW; Kocmond K; Kohlway A; Weidler J; Bates M; Corless C
    Anticancer Res; 2020 Nov; 40(11):6229-6236. PubMed ID: 33109560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using Methylation-Specific PCR to Study RB1 Promoter Hypermethylation.
    McCormick TM; Carvalho MDGDC
    Methods Mol Biol; 2018; 1726():29-34. PubMed ID: 29468541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
    Christmann M; Nagel G; Horn S; Krahn U; Wiewrodt D; Sommer C; Kaina B
    Int J Cancer; 2010 Nov; 127(9):2106-18. PubMed ID: 20131314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
    Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
    PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.
    Piperi C; Themistocleous MS; Papavassiliou GA; Farmaki E; Levidou G; Korkolopoulou P; Adamopoulos C; Papavassiliou AG
    Mol Med; 2010; 16(1-2):1-9. PubMed ID: 19809523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
    Hanihara M; Miyake K; Watanabe A; Yamada Y; Oishi N; Kawataki T; Inukai T; Kondo T; Kinouchi H
    Clin Epigenetics; 2020 Nov; 12(1):174. PubMed ID: 33203454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection and reporting of RB1 promoter hypermethylation in diagnostic screening.
    Price EA; Kolkiewicz K; Patel R; Hashim S; Karaa E; Scheimberg I; Sagoo MS; Reddy MA; Onadim Z
    Ophthalmic Genet; 2018 Aug; 39(4):526-531. PubMed ID: 29851531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Epigenetic regulation in glioblastomas].
    Quillien V
    Ann Pathol; 2009 Nov; 29 Spec No 1():S34-6. PubMed ID: 19887247
    [No Abstract]   [Full Text] [Related]  

  • 59. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
    Lee JY; Park CK; Park SH; Wang KC; Cho BK; Kim SK
    Childs Nerv Syst; 2011 Nov; 27(11):1877-83. PubMed ID: 21789683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component.
    Chkheidze R; Raisanen J; Gagan J; Richardson TE; Pinho MC; Raj K; Achilleos M; Slepicka C; White CL; Evers BM; Patel TR; Malter JS; Hatanpaa KJ
    J Neuropathol Exp Neurol; 2021 Dec; 80(12):1092-1098. PubMed ID: 34850045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.